1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 20,200 | 20,600 | 11:03 | |
| 20,200 | 20,600 | 10:59 |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 07.11. | Spyre Therapeutics, Inc.: Spyre Therapeutics Announces Grants of Inducement Awards | 1 | GlobeNewswire (USA) | ||
| SPYRE THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| 04.11. | Spyre Therapeutics GAAP EPS of -$0.15 beats by $0.61 | 6 | Seeking Alpha | ||
| 04.11. | Spyre Therapeutics reports positive interim data for IBD drug SPY003 | 2 | Investing.com | ||
| 04.11. | Spyre Therapeutics, Inc.: Spyre Therapeutics Announces Positive Interim Phase 1 Results for SPY003, Its Novel, Half-Life Extended anti-IL-23 Antibody | 28 | GlobeNewswire (Europe) | SPY003 was well tolerated and exhibited an ~85-day half-life, supporting potential quarterly or twice annual maintenance dosing SPY003 positive interim results unlock development of SPY130 (a4ß7 +... ► Artikel lesen | |
| 04.11. | Spyre Therapeutics, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 04.11. | Spyre Therapeutics, Inc. - 10-Q, Quarterly Report | - | SEC Filings | ||
| 24.10. | Spyre Therapeutics, Inc.: Spyre Therapeutics Announces Poster Presentations at American College of Rheumatology (ACR) Convergence 2025 | 1 | GlobeNewswire (USA) | ||
| 15.10. | Spyre Therapeutics, Inc. Announces Closing of Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares for Gross Proceeds of $316.2 Million | 1 | GlobeNewswire (USA) | ||
| 14.10. | Spyre Therapeutics Stock Rises 11% After $275 Mln Public Offering Pricing | 1 | RTTNews | ||
| 14.10. | Spyre Therapeutics, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 14.10. | Spyre Therapeutics prices public offering of 14.8M shares at $18.50 to raise $275M | 1 | Seeking Alpha | ||
| 14.10. | Spyre Therapeutics legt Preis für Aktienangebot auf 18,50 US-Dollar fest | 1 | Investing.com Deutsch | ||
| 14.10. | Spyre Therapeutics prices public offering at $18.50 per share | 2 | Investing.com | ||
| 14.10. | Spyre Therapeutics, Inc.: Spyre Therapeutics Announces Pricing of $275.0 Million Public Offering of Common Stock | 1 | GlobeNewswire (USA) | ||
| 13.10. | Spyre Therapeutics announces common stock offering | 1 | Investing.com | ||
| 13.10. | Spyre Therapeutics announces public offering of common stock and pre-funded warrants | 1 | Seeking Alpha | ||
| 13.10. | Spyre Therapeutics kündigt öffentliche Platzierung von Stammaktien an | 2 | Investing.com Deutsch | ||
| 13.10. | Spyre Therapeutics, Inc.: Spyre Therapeutics Announces Proposed Public Offering of its Common Stock and Pre-Funded Warrants | 1 | GlobeNewswire (USA) | ||
| 10.10. | IBM introduces Spyre AI accelerator to market | 6 | eeNews Europe | ||
| 08.10. | IBM's big iron to get Spyre AI accelerator upgrade this month | 12 | The Register |
1 2 3 Weiter >>
50 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| ORUKA THERAPEUTICS | 25,600 | +9,40 % | Oruka Therapeutics, Inc.: Oruka Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update | ORKA-001 Phase 1 results presented at EADV show potential for once-per-year dosing, higher efficacy and off-treatment remission Over $500M cash and equivalents provides runway over one year past three... ► Artikel lesen | |
| PALVELLA THERAPEUTICS | 83,50 | 0,00 % | Raymond James upgrades Palvella Therapeutics stock rating to Strong Buy | ||
| DIANTHUS THERAPEUTICS | 36,200 | +2,84 % | Dianthus Therapeutics, Inc.: Dianthus Therapeutics Highlights Recent Business Achievements and Reports Q3 Financial Results | Claseprubart achieved statistically significant and clinically meaningful improvements in Myasthenia Gravis Activities of Daily Living (MG-ADL), Quantitative Myasthenia Gravis (QMG), and other efficacy... ► Artikel lesen | |
| LENZ THERAPEUTICS | 27,720 | 0,00 % | LENZ Therapeutics, Inc.: LENZ Therapeutics Announces Commercial Product Availability of VIZZ in the United States | VIZZ sample distribution initiated nationwide to Eye Care Professionals Commercial product shipments to be initiated in October to consumers with broad product availability by mid-Q4 2025 VIZZ is... ► Artikel lesen | |
| COGENT BIOSCIENCES | 34,700 | 0,00 % | COGT Stock Skyrockets 120% in a Month: Here's What You Need to Know | ||
| ARCELLX | 89,57 | 0,00 % | Arcellx stock initiated at Peerperform by Wolfe Research amid BCMA market competition | ||
| PRAXIS PRECISION MEDICINES | 164,31 | 0,00 % | Praxis Precision Medicines, Inc.: Praxis Precision Medicines to Participate in Upcoming Fireside Chat | ||
| TARSUS PHARMACEUTICALS | 76,98 | 0,00 % | Mizuho initiates coverage on Tarsus Pharmaceuticals stock with Outperform rating | ||
| VERA THERAPEUTICS | 27,870 | -2,38 % | Vera Therapeutics Submits Biologics License Application to U.S. FDA through Accelerated Approval Program for Atacicept for the Treatment of Adults with IgA Nephropathy | Atacicept received FDA Breakthrough Therapy Designation for the treatment of IgANORIGIN Phase 3 trial met its primary endpoint at the prespecified interim analysis of proteinuria reduction with 46%... ► Artikel lesen | |
| AVIDITY BIOSCIENCES | 70,64 | 0,00 % | Novartis CEO paid top dollar for Avidity to become a 'leader in neuromuscular diseases' | ||
| OLEMA PHARMACEUTICALS | 21,995 | 0,00 % | Biotech-Party! Olema-Aktie explodiert über 136 Prozent - die Hintergründe | Prämie dank Übernahme? Spektakuläre Studienergebnisse? Es ist keine Seltenheit, dass Biotech-Titel aus dem Stand an einem Tag prozentual dreistellig an Wert gewinnen können. Bei Olema Pharmaceuticals... ► Artikel lesen | |
| ANNEXON | 4,270 | 0,00 % | Annexon stock rises after director purchases shares | ||
| DAY ONE BIOPHARMACEUTICALS | 8,290 | 0,00 % | Day One Biopharmaceuticals, Inc.: Day One to Acquire Mersana Therapeutics to Advance Mission to Bring New Medicines to People of All Ages with Life-Threatening Diseases | Acquisition expands Day One's portfolio with novel antibody-drug conjugate (ADC) emiltatug ledadotin (Emi-Le) Emi-Le has demonstrated early anti-tumor activity in an ongoing Phase 1 study for adenoid... ► Artikel lesen | |
| RECURSION PHARMACEUTICALS | 3,845 | 0,00 % | Is Recursion Pharmaceuticals a Meme Stock? | ||
| QIAGEN | 39,945 | +1,28 % | JEFFERIES stuft QIAGEN NV auf 'Buy' | NEW YORK (dpa-AFX Analyser) - Das Analysehaus Jefferies hat die Einstufung für Qiagen mit einem Kursziel von 57 US-Dollar auf "Buy" belassen. Die Profitabilität dürfte 2026 zumindest stabil bleiben... ► Artikel lesen |
Das Unternehmen SPYRE THERAPEUTICS INC kann der Branche Biotechnologie zugeordnet werden. Die relative Kursveränderung beträgt aktuell -0,98 % bei einem Aktienkurs von 20,200 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu SPYRE THERAPEUTICS INC finden Sie auf Wallstreet Online.